Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer.
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2016
At a glance
- Drugs PMZ 1620 (Primary) ; Docetaxel
- Indications Biliary cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 20 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 21 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Mar 2015 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov